Live Breaking News & Updates on Post Venetoclax Patients

Stay updated with breaking news from Post venetoclax patients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the. ....

United States , South San Francisco , David Rosen , Jorgee Cortes , Raul Rodriguez , Cecilf Whitaker Jr , Rigel Pharmaceuticals Inc , American Cancer Society , European Medicines Agency , Exchange Commission , Georgia Cancer Center , Prnewswire Rigel Pharmaceuticals Inc , Scholar Chair , Full Prescribing Information , Rigel Pharmaceuticals , American Cancer , Key Statistics , Acute Myeloid Leukemia , Revised January , Acute Myeloid Leukaemia , Post Venetoclax Patients , Annual Report ,

Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®. ....

United States , South San Francisco , Jorgee Cortes , Cecilf Whitaker Jr , David Rosen , Raul Rodriguez , Exchange Commission , Drug Administration , American Cancer Society , Georgia Cancer Center , European Hematology Association , Prnewswire Rigel Pharmaceuticals Inc , Rigel Pharmaceuticals Inc , Scholar Chair , Post Venetoclax Patients , Practice Guidelines , Full Prescribing Information , Rigel Pharmaceuticals , American Cancer , Key Statistics , Acute Myeloid Leukemia , Revised January , Acute Myeloid Leukaemia , Quarterly Report ,